Journal: BMC Immunology
Article Title: Wnt expression and canonical Wnt signaling in human bone marrow B lymphopoiesis
doi: 10.1186/1471-2172-7-13
Figure Lengend Snippet: Wnt3A inhibits in vitro B lymphopoiesis . BM CD133 + CD10 - HPC (A: assay 1) or CD10 + B progenitor cells (B: assay 2) were cocultured with a confluent layer of the murine stromal cell line MS-5 for 3 or 2 weeks, respectively, while treated with Wnt3A (100 ng/ml), Wnt3A + sFRP1 (2 μg/ml), Wnt3A + Dkk1 (500 ng/ml) or medium only. The number of resulting CD19 + B lineage cells in each sample was determined by quantitative flow cytometry. The percentage of CD34 + cells among the CD19 + cells were measured before and after culturing, with and without treatment with Wnt3A (C). The bars represent the mean of N experiments performed in duplicate, ± SEM. A) N = 6. B) Cells treated with control medium or Wnt3A: N = 11, Wnt3A + sFRP1: N = 3, Wnt3A + Dkk1: N = 2. C) day 0: N = 7, day 7: N = 3, Day 14: N = 8. *p ≤ 0.01, Wilcoxon Signed Ranks Test.
Article Snippet: The following monoclonal antibodies (mAbs) were used for flow cytometry: anti-CD34 PE, anti-CD10 APC, anti-CD10 PE-Cy7 and anti-CD20 APC from Becton Dickinson, Biosciences Pharmingen (San Jose, CA, USA), anti-CD19 PE-Cy5 and anti-CD34 PE-Cy5 from Immunotech (Marseille, France) and anti-CD19 PE, anti-CD45 PE and anti-IgM Fitc from Dako Cytomation (Denmark).
Techniques: In Vitro, Flow Cytometry